07 Feb Immunotherapy Shortage for High-Risk Neuroblastoma
New Zealand is currently investigating solutions for a shortage of dinutuximab (Unituxin, ch14.18), a FDA-approved chimeric monoclonal antibody that is used to prolong the survival of children with high-risk neuroblastoma.
Click here for an update from NCCN on this shortage and steps being taken to identify a solution.